GlassScriptPhysician profile
Carlos Perez
NPI 1528225638
$763.13
in general payments reported to CMS, 2019-2025
30 companies · $64.32 in 2025
The $64.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.63 · 2021: $25.16 · 2023: $215 · 2024: $405 · 2025: $64.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $97.46 | 2023-2024 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $70.82 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $65.79 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $53.63 | 2020 | |
| Amgen INC. | $49.66 | 2023-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $42.82 | 2024 | Farxiga |
| Novo Nordisk INC | $40.18 | 2023-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $39.60 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $34.64 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $25.16 | 2021 | |
| Abbott Laboratories | $24.40 | 2024 | Alinity M |
| Azurity Pharmaceuticals, INC. | $24.13 | 2025 | Azmiro |
| Optinose US, INC. | $23.99 | 2025 | |
| Abbvie INC. | $22.50 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.94 | 2024 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.82 | 2024 | Dexcom G6 Transmitter |
| Halozyme INC | $19.29 | 2023 | |
| Pfizer INC. | $18.96 | 2023 | |
| Baxter Healthcare | $17.63 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Ardelyx, INC. | $17.32 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $16.20 | 2025 | Ultomiris |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.